Przepiorka D, LeParc G F, Stovall M A, Werch J, Lichtiger B
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston, USA.
Am J Clin Pathol. 1996 Jul;106(1):6-11. doi: 10.1093/ajcp/106.1.6.
Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare but fatal potential complication of transfusions. It is mediated by immunocompetent donor lymphocytes that cannot be eliminated by the recipient. Patients at risk for developing TA-GVHD are those who have a profound deficiency in cell-mediated immunity or those who share histocompatibility antigens with the donor and do not recognize the donor cells as foreign. Irradiation of cellular blood components is currently the only acceptable method for prevention of TA-GVHD. This practice guideline identifies the patient population who should receive irradiated blood components and describes the technical aspects of blood component irradiation that may affect the safety of the final product.
输血相关移植物抗宿主病（TA-GVHD）是一种罕见但致命的输血潜在并发症。它由免疫活性供体淋巴细胞介导，而这些淋巴细胞不能被受者清除。有发生TA-GVHD风险的患者是那些细胞介导免疫严重缺陷的患者，或者是那些与供体共享组织相容性抗原且不将供体细胞识别为外来细胞的患者。目前，对细胞血液成分进行辐照是预防TA-GVHD的唯一可接受方法。本实践指南确定了应接受辐照血液成分的患者群体，并描述了可能影响最终产品安全性的血液成分辐照技术方面。
